georgie18
2週前
IMRX...$2.08...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 100
Friday, December 20, 2024 12:44:19 PM
Post#
102
of 102
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...
georgie18
Member Level
Re: georgie18 post# 386949
Monday, December 16, 2024 9:52:41 AM
Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...
georgie18
Member Level
Re: georgie18 post# 98
Friday, December 13, 2024 2:49:56 PM
Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...
georgie18
Member Level
Re: georgie18 post# 384375
Friday, December 13, 2024 9:47:27 AM
Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...
georgie18
Member Level
Re: georgie18 post# 84
Tuesday, October 15, 2024 8:48:58 AM
Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
georgie18
2週前
IMRX...$2.00...🥳...Tring to Breakout here...Off the $15.2 range Gap Fill...
georgie18
Member Level
Re: georgie18 post# 386949
Monday, December 16, 2024 9:52:41 AM
Post#
386990
of 387312
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...
georgie18
Member Level
Re: georgie18 post# 98
Friday, December 13, 2024 2:49:56 PM
Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...
georgie18
Member Level
Re: georgie18 post# 384375
Friday, December 13, 2024 9:47:27 AM
Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...
georgie18
Member Level
Re: georgie18 post# 84
Tuesday, October 15, 2024 8:48:58 AM
Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
georgie18
2週前
IMRX...$1.75...🥳...Bouncing off the Gap fill...Looking to fill the Gap up top in the $1.90 Range...
georgie18
Member Level
Re: georgie18 post# 98
Friday, December 13, 2024 2:49:56 PM
Post#
99
of 99
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...
georgie18
Member Level
Re: georgie18 post# 384375
Friday, December 13, 2024 9:47:27 AM
Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...
georgie18
Member Level
Re: georgie18 post# 84
Tuesday, October 15, 2024 8:48:58 AM
Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
georgie18
3週前
IMRX...$1.52...Gap filled...🥳...Open Gap up in the $1.90 range...that will fill...
georgie18
Member Level
Re: georgie18 post# 384375
Friday, December 13, 2024 9:47:27 AM
Post#
386929
of 386949
IMRX...$1.72...🥳...On the Gap fill...
georgie18
Member Level
Re: georgie18 post# 84
Tuesday, October 15, 2024 8:48:58 AM
Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
georgie18
3週前
IMRX...$1.72...🥳...On the Gap fill...
georgie18
Member Level
Re: georgie18 post# 84
Tuesday, October 15, 2024 8:48:58 AM
Post#
86
of 97
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
tw0122
2月前
In some again 21m float $1.76 has enough cash to fund operations through 2025. Based on cash, cash equivalents and marketable securities as of September 30, 2024, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2025. Positive developments ..
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients -- Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer -
- Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End -- Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates.“We were extremely pleased to share positive initial response data in September for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in pancreatic cancer as part of the ongoing Phase 2a clinical trial,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “While still early, it is highly encouraging to already see responses – including a complete response – as well as impressive disease control, both at levels that would represent a meaningful improvement over the existing standard of care. If these results continue, we believe we will have a clear path forward for clinical development of IMM-1-104 in combination with gemcitabine/nab-paclitaxel for pancreatic cancer. Importantly, our recent Fast Track and Orphan Drug designations from the FDA may help advance development of this potentially important new therapy for the treatment of pancreatic cancer. With enrollment progressing well in our Phase 2a arms, we expect to share further data by year end and we look forward to providing updates on our progress at that time.”Corporate HighlightsFDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer: In October 2024, the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to IMM-1-104 in the treatment of pancreatic cancer.
Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients: In September 2024, Immuneering announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial. If the early trends with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel continue, management believes there is a clear path forward for clinical development of IMM-1-104 in pancreatic cancer, which has the potential to improve the prognosis for a drastically underserved patient population.
FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer: In July 2024, the FDA granted Fast Track designation for IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).
Near-Term Milestone Expectations IMM-1-104Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
IMM-6-415Initial PK, PD and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.
Third Quarter 2024 Financial Highlights Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2024 were $50.7 million, compared with $85.7 million as of December 31, 2023. The September 30, 2024 figure includes $4.2 million of net proceeds from the Company’s ATM facility.Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2024 were $11.3 million, compared with $10.1 million for the third quarter of 2023. The increase in R&D expenses was primarily attributable to higher clinical costs related to the Company’s lead program and increased personnel to support ongoing research and development activities.General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2024 were $4.0 million, compared with $3.9 million for the third quarter of 2023. The increase in G&A expenses was primarily attributable to an increase in the Company’s stock-based compensation costs and employee-related costs in connection with general and administrative functions.Net Loss: Net loss attributable to common stockholders was $14.6 million, or $0.49 per share, for the third quarter ended September 30, 2024, compared to $12.6 million, or $0.43 per share, for the third quarter ended September 30, 2023.2024 Financial Guidance Based on cash, cash equivalents and marketable securities as of September 30, 2024, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2025.
georgie18
3月前
IMRX...$2.58 ...on News...$1.86 Dip partially filled the gap...🥳
CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer, in which positive initial response data was recently reported for first line pancreatic cancer patients treated in combination with modified gemcitabine/nab-paclitaxel.
herbied47
3月前
Swing idea. AZTR small float, recently received study may proceed letter from the FDA for INDA to treat skin rash from EGFR inhibitors, , recent offering at 1.50, recently announced three newly patents in US, China and Canada to treat inflammatory skin diseases, recent 1/30 reverse split, Maxim Group Buy rating, price target $3
georgie18
3月前
IMRX...$3.28...on the 200ma Break...Still bidding the open gap as well to hedge my bets...🥳
georgie18
Member Level
Re: georgie18 post# 383711
Friday, September 20, 2024 12:40:35 PM
Post#
383713
of 383715
IMRX...$3.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 658202
Friday, September 20, 2024 10:45:43 AM
Post#
658620
of 658665
IMRX...$3.05s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 383579
Wednesday, September 18, 2024 10:08:32 AM
Post#
383624
of 383710
IMRX...$2.55...Still bidding the Open Gap....🥳...First alerted at $1.02 and ran to $3.50 range...Took most off the table in the $2.10 range...
georgie18
Member Level
Re: georgie18 post# 657838
Monday, September 16, 2024 3:18:13 PM
Post#
657880
of 658201
IMRX...$3.50s clearing here...🥳...on the 200ma Break...Beauty pop off the $1.80 range dip...First alert at $1.02...
georgie18
Member Level
Re: georgie18 post# 383555
Monday, September 16, 2024 1:23:52 PM
Post#
383573
of 383577
IMRX...$2.58s clearing here...🥳...
georgie18
Member Level
Re: georgie18 post# 657547
Monday, September 16, 2024 7:12:05 AM
Post#
657757
of 657837
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
3月前
IMRX...$3.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 658202
Friday, September 20, 2024 10:45:43 AM
Post#
658620
of 658665
IMRX...$3.05s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 383579
Wednesday, September 18, 2024 10:08:32 AM
Post#
383624
of 383710
IMRX...$2.55...Still bidding the Open Gap....🥳...First alerted at $1.02 and ran to $3.50 range...Took most off the table in the $2.10 range...
georgie18
Member Level
Re: georgie18 post# 657838
Monday, September 16, 2024 3:18:13 PM
Post#
657880
of 658201
IMRX...$3.50s clearing here...🥳...on the 200ma Break...Beauty pop off the $1.80 range dip...First alert at $1.02...
georgie18
Member Level
Re: georgie18 post# 383555
Monday, September 16, 2024 1:23:52 PM
Post#
383573
of 383577
IMRX...$2.58s clearing here...🥳...
georgie18
Member Level
Re: georgie18 post# 657547
Monday, September 16, 2024 7:12:05 AM
Post#
657757
of 657837
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
3月前
IMRX...$3.05s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 383579
Wednesday, September 18, 2024 10:08:32 AM
Post#
383624
of 383710
IMRX...$2.55...Still bidding the Open Gap....🥳...First alerted at $1.02 and ran to $3.50 range...Took most off the table in the $2.10 range...
georgie18
Member Level
Re: georgie18 post# 657838
Monday, September 16, 2024 3:18:13 PM
Post#
657880
of 658201
IMRX...$3.50s clearing here...🥳...on the 200ma Break...Beauty pop off the $1.80 range dip...First alert at $1.02...
georgie18
Member Level
Re: georgie18 post# 383555
Monday, September 16, 2024 1:23:52 PM
Post#
383573
of 383577
IMRX...$2.58s clearing here...🥳...
georgie18
Member Level
Re: georgie18 post# 657547
Monday, September 16, 2024 7:12:05 AM
Post#
657757
of 657837
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
3月前
IMRX...$2.55...Still bidding the Open Gap....🥳...First alerted at $1.02 and ran to $3.50 range...Took most off the table in the $2.10 range...
georgie18
Member Level
Re: georgie18 post# 657838
Monday, September 16, 2024 3:18:13 PM
Post#
657880
of 658201
IMRX...$3.50s clearing here...🥳...on the 200ma Break...Beauty pop off the $1.80 range dip...First alert at $1.02...
georgie18
Member Level
Re: georgie18 post# 383555
Monday, September 16, 2024 1:23:52 PM
Post#
383573
of 383577
IMRX...$2.58s clearing here...🥳...
georgie18
Member Level
Re: georgie18 post# 657547
Monday, September 16, 2024 7:12:05 AM
Post#
657757
of 657837
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
4月前
IMRX...$3.50s clearing here...🥳...on the 200ma Break...Beauty pop off the $1.80 range dip...First alert at $1.02...
georgie18
Member Level
Re: georgie18 post# 383555
Monday, September 16, 2024 1:23:52 PM
Post#
383573
of 383577
IMRX...$2.58s clearing here...🥳...
georgie18
Member Level
Re: georgie18 post# 657547
Monday, September 16, 2024 7:12:05 AM
Post#
657757
of 657837
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
4月前
IMRX...$2.58s clearing here...🥳...
georgie18
Member Level
Re: georgie18 post# 657547
Monday, September 16, 2024 7:12:05 AM
Post#
657757
of 657837
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
4月前
IMRX...$2.05...Bidding the Open Gap...Following the $1.02 alert...ran to $2.50 range...🥳...
georgie18
Member Level
Re: georgie18 post# 383519
Friday, September 13, 2024 9:56:02 AM
Post#
383527
of 383554
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
georgie18
4月前
IMRX...$2.36s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 657304
Thursday, September 12, 2024 5:27:23 PM
Post#
657462
of 657546
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s
axelvento
4月前
To date, the first two patients in the Phase 2a arm evaluating IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer have recorded complete or partial responses for an initial response rate of 40% (2/5) and disease control rate of 80% (4/5), with the other three patients earlier in the course of treatment and all five continuing on treatment.
Benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients were established by the Phase 3 MPACT study, which included 1 Complete Response (CR) out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate1. Benchmarks for modified (m) Gemcitabine/nab-Paclitaxel include an 18.6% ORR2.
To date, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel was observed to be well tolerated, with an emerging safety profile in line with known data for both therapeutics respectively.
Based on safety data to date, the trial’s Data and Safety Monitoring Board (DSMB) has approved enrolling additional patients into this arm at 320mg QD p.o., the first of which have already been dosed and are awaiting first scans.
- Enrollment progressing in all Phase 2a arms with further data expected by year end -
https://ir.immuneering.com/news-releases/news-release-details/immuneering-announces-positive-initial-phase-2a-data-including
georgie18
4月前
IMRX...$2.17...on News...https://www.globenewswire.com/news-release/2024/09/12/2945572/0/en/Immuneering-Announces-Positive-Initial-Phase-2a-Data-Including-Complete-and-Partial-Responses-with-IMM-1-104-in-Combination-with-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patien.html
georgie18
Member Level
Re: georgie18 post# 383470
Thursday, September 12, 2024 11:04:45 AM
Post#
383494
of 383519
IMRX...$1.42s clearing here at HOD...🥳...Upper Bollie Breakout...
georgie18
Member Level
Re: georgie18 post# 656376
Wednesday, September 11, 2024 4:13:13 PM
Post#
657184
of 657302
IMRX...$1.28...Closed HOD...🥳...Break/Hold $1.37 and she will see $1.70 range pretty quickly...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 47
Wednesday, September 04, 2024 5:00:51 PM
Post#
48
of 52
IMRX...$1.26...Hit $1.33 Today...🥳...
georgie18
Member Level
Re: georgie18 post# 656149
Tuesday, September 03, 2024 12:11:44 PM
Post#
656178
of 656375
IMRX...$1.23s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 42
Tuesday, September 03, 2024 9:21:22 AM
Post#
45
of 46
IMRX...$1.18s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 655310
Thursday, August 29, 2024 11:03:56 AM
Post#
655765
of 656148
IMRX...$1.15...Bollie Squeeze setting up here...🥳..Break/Hold $1.21 and she will go...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 40
Monday, August 26, 2024 8:01:28 PM
Post#
41
of 41
IMRX...$1.17...slowly moving up from the $1.02 alert... 🥳added $1.08s...
tw0122
4月前
Nevertheless, it was encouraging to see a complete response in the very first pancreatic cancer patient treated with IMM-1-104 in this combination, with the patient now on treatment for over six months,” said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering. “Looking at the bigger picture, our Phase 2a trial aims to evaluate the efficacy of IMM-1-104 in multiple settings across various tumor types, to identify the highest priority opportunities for future development. If the early trends with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel continue, we will have an exciting direction for potential future development of IMM-1-104, which could greatly improve the prognosis for a drastically underserved patient population.”
Initial Results from Phase 2a Arm Evaluating IMM-1-104 with Modified Gemcitabine/nab-Paclitaxel in First Line Pancreatic Cancer as of September 12, 2024
Patient MAPK
Mutation
Variant Dose (p.o.)
Level for
IMM-1-104 %
Change
in SLD
1st Scan %
Change
in SLD
2nd Scan %
Change
in SLD
3rd Scan %
Change
in SLD
4th Scan %
Change
in SLD
5th Scan ORR/
RECIST
1 GNAS-T105Vfs*3 (*) 240mg QD -100% -100% -100% -100% next
scan CR
2 KRAS-G12V* 240mg QD -8% -10% -40% next
scan uPR°
3 KRAS-G12V* 240mg QD -4% next
scan SD
4 Unk.# 240mg QD +6% next
scan SD
5 KRAS-G12R* 240mg QD -9% next
scan eqPD**
Initial Overall Response Rate
(ORR): 40%
Initial Disease Control Rate (DCR): 80%
* Detected in plasma cfDNA or prior genomic test.
# Unknown (Unk.); MAPK pathway variant not detected in plasma cfDNA or prior genomic test.
° Partial response result classified as “unconfirmed” pending subsequent scan.
**Equivocal (eq); Patient not dosed for over two weeks during hospitalization for a preexisting condition. Scans showed ascites and a pleural effusion categorized by radiology as equivocal new lesions per RECIST 1.1. The investigator determined these to be related to the recent placement of a hepatic stent, not disease progression, and stated that the patient is improving and remains on therapy.
Source: Immuneering Corporation
To date, the first two patients in the Phase 2a arm evaluating IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer have recorded complete or partial responses for an initial response rate of 40% (2/5) and disease control rate of 80% (4/5), with the other three patients earlier in the course of treatment and all five continuing on treatment.
Benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients were established by the Phase 3 MPACT study, which included 1 Complete Response (CR) out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate1. Benchmarks for modified (m) Gemcitabine/nab-Paclitaxel include an 18.6% ORR2.
To date, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel was observed to be well tolerated, with an emerging safety profile in line with known data for both therapeutics respectively.
Based on safety data to date, the trial’s Data and Safety Monitoring Board (DSMB) has approved enrolling additional patients into this arm at 320mg QD p.o., the first of which have already been dosed and are awaiting first scans.
[1] Von Hoff, et al. N Engl J Med. 2013;369:1691-1703, [2] Ahn DH, et al. Therapeutic Advances in Medical Oncology. 2017;9(2):75-82
“These exciting early clinical findings are consistent with the preclinical data we shared at AACR earlier this year, which pointed to synergies between IMM-1-104 and chemotherapeutics - driving deeper more durable responses than either can achieve alone,” said Brett Hall, Ph.D., Chief Scientific Officer, Immuneering Corporation. “If the combination data for IMM-1-104 continues to be positive – and taking into account the excellent emerging safety profile for IMM-1-104 – one can imagine the drug’s potential inclusion in various vertical drug combinations, immune-modifying combinations, and orthogonal combinations with therapeutics with non-overlapping mechanisms of action, which Immuneering may in the future develop both on its own and in partnership with third parties.”
“There is a high unmet need in pancreatic cancer for novel therapies that meaningfully improve outcomes. With current therapies in pancreatic cancer, we rarely see complete responses, and as such any treatment that leads to one is exciting and deserves further investigation, particularly when observed in the setting of a well-tolerated agent such as IMM-1-104,” said Tanios Bekaii-Saab, M.D., Leader of the Gastrointestinal Cancer Disease Group for the Mayo Clinic Cancer Center enterprise wide and Medical Oncology consultant in Mayo Clinic in Phoenix, Arizona.
In the Phase 2a portion of Immuneering’s ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in combination with approved chemotherapeutic agents. The Phase 2a portion includes five arms, one of which focuses on patients with RAS mutant melanoma, another on patients with RAS mutant non-small cell lung cancer (NSCLC), and three arms focused on patients with pancreatic cancer. Immuneering previously announced that IMM-1-104 received fast track designation for the treatment of first- and second-line pancreatic cancer.
Near-Term Milestone Expectations
IMM-1-104
Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
IMM-6-415
Initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.
Conference Call
Immuneering will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on September 12, 2024, to discuss the results and provide a busin
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
glenn1919
2週前
81vette
3月前
Capitalvaluetrade
3月前
